MODIFIED MATRIX PROTEINS OF VESICULAR STOMATITIS VIRUS

Title:

MODIFIED MATRIX PROTEINS OF VESICULAR STOMATITIS VIRUS

Document Type and Number:

WIPO Patent Application WO/2014/205579

Kind Code:

A4

Abstract:

The present invention relates to vesicular stomatitis virus (VSV) matrix (M) protein mutants. One mutant M protein includes a glycine changed to a glutamic acid at position (21), a leucine changed to alanine at position (111) and a methionine changed to an arginine at position (51). Another M protein mutant includes a glycine changed to a glutamic acid at position (22) and a methionine changed to an arginine at positions (48) and (51). These new rVSVs having the mutant M are significantly attenuated and lost virulence, including neurovirulence, and are capable of inducing an immune responses against an antigen of interest. In addition, a rVSV serotype Indiana having the first described M mutant is capable of efficient replication at 31°C, and of poor replication or incapable of replication at about 37°C or higher.

More Like This:

WO/2023/015710	RABIES VIRUS VACCINE AND PREPARATION METHOD THEREFOR
WO/2000/006751	REPRESSOR PROTEINS PRODUCING CELL LINES FOR THE PROPAGATION OF VECTORS
WO/2015/062171	MONOCLONAL ANTIBODY AND ANTIGEN AND GENE THEREOF, AND USES THEREOF

Inventors:

KANG CHIL-YONG (CA)
KIM GYOUNG NYOUN (CA)

Application Number:

PCT/CA2014/050614

Publication Date:

February 12, 2015

Filing Date:

June 26, 2014

Export Citation:

Click for automatic bibliography generation Help

Assignee:

UNIV WESTERN ONTARIO (CA)

International Classes:

C12N15/47; A61K39/205; A61K39/21; A61K39/295; A61K39/39; A61P31/14; A61P37/04; C07K14/145; C12N7/01

Attorney, Agent or Firm:

KRUPNIK, Eduardo (London, Ontario N6A5R8, CA)

Download PDF:

View/Download PDF PDF Help

Claims:

AMENDED CLAIMS

received by the International Bureau on 31 December 2014

(31.12.2014)

What is claimed is:

1. A modified matrix (M) protein of a vesicular stomatitis virus (VSV), wherein the modified M protein comprises an amino acid sequence selected from: (i) SEQ ID NO: 3 including at least the following substitutions: G21E/L111A/M51 R; and (ii) SEQ ID NO: 8 including at least the following substitutions: G22E/L110A M48R/ 51 R.

2. The modified M protein of claim 1, wherein the modified M protein of (i) comprises an amino acid sequence SEQ ID NO:4 and the modified M protein of (ii) comprises the amino acid sequence SEQ ID NO: 10.

3. The modified M protein of claim 1 , wherein the E at position 21 in (i) and the E at position 22 in (ii) are encoded by a gaa codon, and wherein the R at position 51 in (i) and (ii) and the R at position 48 in (ii) is encoded by a cga codon.

4. The modified M protein of claim 1 , wherein the A at position 111 in (i) and the A at position 110 in (ii) is encoded by a gca codon.

5. The modified M protein of claim 1 , wherein the amino acid sequence of (i) is encoded by a gene comprising SEQ ID NO:2, and the amino acid sequence of (ii) is encoded by a gene comprising SEQ ID NO:7.

6. A nucleotide sequence that encodes for a modified matrix protein of a vesicular stomatitis virus, wherein the nucleotide sequence comprises a sequence selected from: SEQ ID NO.2, SEQ ID NO:6 and SEQ ID NO:7.

7. A recombinant vesicular stomatitis virus (rVSV), wherein said rVSV includes a nucleotide sequence that encodes for a modified matrix (M) protein, the nucleotide sequence comprising a sequence selected from SEQ ID NO:2, SEQ ID NO:6 and SEQ ID NO:7.

8. A recombinant vesicular stomatitis virus (rVSV), wherein said rVSV comprises a modified matrix (M) protein, the modified M protein comprising an amino acid sequence selected from: (i) SEQ ID NO: 3 including at least the following substitutions: G21E/L111A/M51 R; and (ii) SEQ ID NO: 8 including at least the following substitutions: G22E/L110A/M48R/M51 R.

9. The rVSV of claim 8, wherein the E at position 21 in (i) and the E at position 22 in (ii) are encoded by a gaa codon, and wherein the R at position 51 in (i) and (ii) and the R at position 48 in (ii) is encoded by a cga codon.

10. The rVSV of claim 8, wherein the A at position 111 in (i) and the A at position 110 in (ii) are encoded by a gca codon.

11. The rVSV of claim 8, wherein said rVSV is a recombinant vesicular stomatitis virus Indiana serotype (rVSV_lnd), and wherein the modified M protein comprises the amino acid sequence of SEQ ID NO: 3 including at least the following substitution: G21E/L111A/M51 R.

12. The rVSV of claim 11, wherein the modified M protein comprises the amino acid sequence of SEQ ID NO: 4.

13. The rVSV of claim 10, wherein the modified M protein is encoded by a gene comprising a nucleotide sequence of SEQ ID NO: 2.

14. The rVSV according to any one of claims 11-13, wherein the rVSVind is capable of producing VSV|_nd particles at permissible temperatures and incapable of producing the particles at non-permissible temperatures.

15. The rVSV of claim 8, wherein said rVSV is a recombinant vesicular stomatitis virus New Jersey serotype (rVSV_NJ), and wherein the modified M protein comprises the amino acid sequence of SEQ ID NO: 8 including at least the following substitutions: G22E/L1 0A 48R/ 51 R.

16. The rVSV of claim 15, wherein the modified M protein is encoded by a gene comprising a nucleotide sequence of SEQ ID NO: 7

17. The rVSV of claim 15, wherein the modified M protein comprises the amino acid sequence SEQ ID NO: 10.

18. The rVSV of claims 8-17, wherein the rVSV is a chimeric rVSV that expresses a protein of a foreign pathogen.

19. The rVSV of claim 18, wherein said pathogen is a viral, fungal, bacterial or parasitic pathogen.

20. The rVSV of claims 7-19, wherein the rVSV is essentially non-cytolytic and avirulent.

21. A vaccine, the vaccine including a modified matrix (M) protein of a vesicular stomatitis virus (VSV) wherein the modified M protein is encoded by a nucleotide sequence comprising a sequence selected from: SEQ ID NO:2, SEQ ID NO;6 and SEQ ID NO:7.

22. A vaccine, wherein the vaccine comprises an effective amount of one or more attenuated recombinant vesicular stomatitis viruses (rVSVs) of claims 7-21.

23. The vaccine of claim 22, wherein said vaccine is capable of inducing a humoral, cellular and mucosal immune response.

24. The vaccine of claim 21 or 22, wherein said vaccine further includes an adjuvant.

25. A prime boost combination vaccine, wherein the prime boost combination vaccine comprises: (a) an effective amount of a vaccine comprising an attenuated recombinant vesicular stomatitis virus (rVSV) of one serotype having a first modified matrix (M) protein comprising the amino acid sequence of SEQ ID N0 4; and (b) an effective amount of a vaccine comprising a rVSV of another serotype having a second modified M protein comprising the amino acid sequence of SEQ ID NO:9 or SEQ ID NO: 10.

26. The prime boost combination vaccine of claim 25, wherein SEQ ID NO:4 is encoded by a gene comprising SEQ ID NO:2.

27. The prime boost combination vaccine of claim 25, wherein SEQ ID NO:9 is encoded by a gene comprising SEQ ID NO:6, and SEQ ID NO: 10 is encoded by a gene comprising SEQ ID NO:7.

28. The prime boost combination vaccine of claim 25, wherein (a) is a priming vaccine and (b) is a booster vaccine.

29. The prime boost combination vaccine of claim 25, wherein (b) is a priming vaccine and (a) is a booster vaccine.

30. The prime boost combination vaccine of claim 25, wherein the two attenuated rVSVs are chimeric rVSVs that express a protein of a foreign pathogen, and wherein the two chimeric rVSVs are capable of inducing an immune response to the protein.

31. The prime boost combination vaccine of claim 30, wherein the pathogen is a viral, a fungal, a bacterial or a parasitic pathogen.

32. The prime boost combination vaccine of claim 30, wherein the pathogen is a lentivirus.

33. The prime boost combination vaccine of claim 32, wherein the lentivirus is a HIV and the protein is a HIV protein.

34. The prime boost combination vaccine of claim 33, wherein the rVSV of one serotype and the rVSV of the other serotype include a surface glycoprotein (G) gene and a RNA dependent RNA polymerase (L) gene, and wherein a gene for expressing the HIV protein is inserted in between the G gene and the L gene.

35. The prime boost combination vaccine of claim 34, wherein the HIV gene is selected from the group of HIV genes consisting of env, gag and pol.

36. The prime boost combination vaccine of claim 32, wherein the pathogen is HCV and the epitope is a HCV protein.

37. The prime boost combination vaccine of claim 36, wherein the rVSV of one serotype and the rVSV of the other serotype include a surface glycoprotein (G) gene and a RNA dependent RNA polymerase (L) gene, and wherein a gene for expressing the HCV protein is inserted in between the G gene and the L gene.

38. The prime boost combination vaccine of claim 37, wherein the HCV protein is a structural or a non-structural HCV protein.

39. The prime boost combination vaccine of any one of claims 30 to 38, wherein each one of the two vaccines comprises a mixture of the attenuated chimeric rVSVs, and wherein at least two of the attenuated chimeric rVSVs in the mixture have a different protein of the pathogen.

40. The prime boost combination vaccine of any one of claims 25 to 39, wherein each one of the two vaccines is capable of inducing humoral, cellular and mucosal immune responses.

41. The prime boost combination vaccine of any one of claims 25 to 40, wherein the serotype of vaccine (a) is Indiana and the serotype of vaccine (b) is New Jersey.

42. The prime boost combination vaccine of any one of claims 25 to 41, wherein each one of vaccine (a) and vaccine (b) further comprises an adjuvant.

43. A kit comprising: (a) at least one dose of an effective amount of a vaccine comprising a recombinant vesicular stomatitis virus Indiana serotype (rVSV|_rtd) having a modified matrix (M) protein comprising the amino acid sequence of SEQ ID NO:4, and (b) at least one dose of an effective amount of a vaccine comprising a recombinant vesicular stomatitis virus New Jersey serotype (rVSV_NJ) having a modified M protein comprising the amino acid sequence of SEQ ID NO:9 or the amino acid sequence of SEQ ID NO: 10.

44. The kit of claim 43, wherein (a) and (b) are formulated in a pharmaceutically acceptable carrier.

45. The kit of claim 43, wherein SEQ ID NO:4 is encoded by a gene comprising SEQ ID NO:2.

46. The kit of claim 43, wherein SEQ ID NO:9 is encoded by a gene comprising SEQ ID NO:6 and SEQ ID NO:10 is encoded by a gene comprising SEQ ID NO:7.

47. An isolated peptide comprising an amino acid sequence selected from the group of amino acid sequences listed as SEQ ID NOs: 4 and 10.

48. An isolated nucleotide sequences comprising a nucleotide sequence selected from the group SEQ ID NO:2, SEQ ID NO:6 and SEQ ID NO:7.

49. A use of the vaccine of claim 21 or 22 to induce an immune response in a subject.

50. A use of the prime boost combination vaccine of claim 25 to induce an immune response in a subject.

Previous Patent: SELF-UNDERCUT ANCHOR SYSTEM

Next Patent: METALLURGICAL VESSELS WITH SEGMENTED, HINGED LIDS